CD40 and cancer: We further analyzed liver-related side effects in patients with cancer receiving these novel therapies alone or in combination with others.<h4>Methods</h4>Clinical studies on immunotherapies targeting molecules such as LAG-3, TIGIT, TIM-3, VISTA, CD47, ICOS, CD40, and B7-H3 were retrieved from PubMed, Embase, Cochrane Library, and Web of Science.